Richard S. Finn, MD, Geffen School of Medicine
Advertisement
Articles by Richard S. Finn, MD, Geffen School of Medicine
Advertisement
Latest Updated Articles
Emerging Biomarkers in Hepatocellular CarcinomaPublished: July 13th 2020 | Updated:
Screening Vs Diagnosis: Assessing Liver FunctionPublished: October 30th 2020 | Updated:
Immunotherapy Monotherapy in Later-Line SettingPublished: October 30th 2020 | Updated:
Regorafenib or Cabozantinib for Second-Line HCCPublished: July 13th 2020 | Updated:
HCC: Emerging Therapies Under InvestigationPublished: July 13th 2020 | Updated:
Hepatocellular Carcinoma: Diagnostic Work-UpPublished: July 13th 2020 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
2
Nonresponse to Bridging Therapy and Peak ALC After Cilta-Cel Are Associated With Neurotoxicity, NRM in Myeloma
3
FDA Updates Axi-Cel Label to Remove Limitation of Use in R/R PCNSL
4
FDA Underscores Risks Associated With DPD Deficiency and Capecitabine/5-FU Use in Cancer Care
5